ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L15

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

David Isenberg1, Richard Furie 2, Nicholas Jones 3, Pascal Guibord 4, Joshua Galanter 5, Chin Lee 3, Anna McGregor 3, Balazs Toth 3, Julie Rae 3, Olivia Hwang 3, Pedro Miranda 6, Viviane de Souza 7, Juan Jaller-Raad 8, Anna Maura Fernandes 9, Rodrigo Garcia Salinas 10, Leslie Chinn 3, Michael Townsend 11, Alyssa Morimoto 3 and Katie Tuckwell 12, 1University College London, London, United Kingdom, 2Northwell Health, Great Neck, NY, 3Genentech, Inc., South San Francisco, California, 4Hoffmann-La Roche Limited, Mississauga, Canada, 5Genentech, Inc., SOUTH SAN FRANCISCO, 6Centro Estudios Reumatologicos, Santiago, Chile, 7Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, 8Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, 9Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, 10Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, 11Genentech, Inc., San Fransisco, 12Genentech, Inc., South San Francisco, CA

Meeting: 2019 ACR/ARP Annual Meeting

Date of first publication: October 23, 2019

Keywords: B cell targeting, Biomarkers, Late-Breaking 2019, Systemic lupus erythematosus (SLE), therapeutic targeting

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Late-Breaking Abstracts ePoster

Session Type: Late-Breaking Abstract Poster Session

Session Time: 9:00AM-11:00AM

Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy, safety, and pharmacodynamic effects of fenebrutinib in patients with moderate-to-severe systemic lupus erythematosus (SLE) activity were assessed in this Phase 2, randomized, placebo-controlled, multi-center study.

Methods: Patients who met SLICC or revised ACR SLE criteria, had ≥1 serologic marker of SLE (ANA, anti-dsDNA, or anti-Smith), SLEDAI ≥6 (later amended to ≥8) at screening, and were on ≥1 standard of care (SOC) therapy (corticosteroid, antimalarial, and/or immunosuppressive) were included; patients with renal or CNS involvement, recent exposure to B cell depleting therapy, or who were receiving a calcineurin inhibitor were excluded. Enrolled patients were randomized to placebo, FEN 150 mg QD, or FEN 200 mg BID, for 48 weeks of therapy. Corticosteroid taper was recommended, with burst and taper permitted from week 0 to week 12 (W0 to W12) and W24 to W36. SRI-4 at W48 was the primary endpoint, comparing the FEN arms with placebo using a sample size of 240 patients targeted for 88% power. BICLA response at W48 was a secondary endpoint.

Results: This study enrolled 260 patients from 44 sites in 12 countries, with the majority of patients recruited in Latin America, USA, and Western Europe. At week 48, the SRI-4 response rates for FEN 150 mg QD and FEN 200 mg BID were 51% (95% CI: -8.5, 21.2) and 52% (95% CI: -7.3, 22.4), respectively, compared to 44% for the placebo arm (Table 1). The week 48 BICLA response rates for FEN 150 mg QD and FEN 200 mg BID were 53% (95% CI: -3.4, 26.8) and 42% (95% CI: -14.2, 16.1), respectively, compared to 41% for the placebo arm (Table 1). Safety results were similar between FEN and placebo, although more serious adverse events were observed in the FEN 200 mg BID arm (Table 1). Treatment with both doses of FEN significantly reduced levels of CD19+ B cells, anti-dsDNA autoantibodies, IgG, and a BTK-dependent RNA signature highly expressed in plasmablasts by week 48 compared to placebo; C4 levels modestly improved with FEN versus placebo (Table 2).

Conclusion: The primary endpoint of SRI-4 for FEN was not met despite evidence of strong BTK target and pathway inhibition. FEN had an acceptable safety profile.


Disclosure: D. Isenberg, Genentech, Inc., 1; R. Furie, Biogen, 5, GlaxoSmithKline, 2, 5, UCB Pharma, 2, 5, Genentech, Inc., 1; N. Jones, Genentech, Inc., 1, 2; P. Guibord, Hoffmann-La Roche Limited, 1, 2; J. Galanter, Genentech, Inc., 1, 2; C. Lee, Genentech, Inc., 1, 2, Eli Lilly, 1; A. McGregor, Genentech, Inc., 1; B. Toth, Genentech, Inc., 1, 2; J. Rae, Genentech, Inc., 1, 2; O. Hwang, Genentech, Inc., 1, 2; P. Miranda, Genentech, Inc., 1; V. de Souza, Genentech, Inc., 1; J. Jaller-Raad, Genentech, Inc., 1; A. Maura Fernandes, Genentech, Inc., 1; R. Garcia Salinas, Genentech, Inc., 1; L. Chinn, Genentech, Inc., 1, 2, 3; M. Townsend, Genentech, Inc., 1, 2; A. Morimoto, Genentech, Inc., 1, 2, 3; K. Tuckwell, Genentech, Inc., 1, 2.

To cite this abstract in AMA style:

Isenberg D, Furie R, Jones N, Guibord P, Galanter J, Lee C, McGregor A, Toth B, Rae J, Hwang O, Miranda P, de Souza V, Jaller-Raad J, Maura Fernandes A, Garcia Salinas R, Chinn L, Townsend M, Morimoto A, Tuckwell K. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-safety-and-pharmacodynamic-effects-of-the-brutons-tyrosine-kinase-inhibitor-fenebrutinib-gdc-0853-in-moderate-to-severe-systemic-lupus-erythematosus-results-of-a-phase-2-rando/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-safety-and-pharmacodynamic-effects-of-the-brutons-tyrosine-kinase-inhibitor-fenebrutinib-gdc-0853-in-moderate-to-severe-systemic-lupus-erythematosus-results-of-a-phase-2-rando/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.